An exploratory clinical study of β-glucan combined with camrelizumab and SOX chemotherapy as first-line treatment for advanced gastric adenocarcinoma

Authors

Chunjian Qi (ORCID: https://orcid.org/0000-0001-9567-112X)
Wenyu Zhu (ORCID: https://orcid.org/0000-0003-4531-2350)
Hua Jiang (ORCID: https://orcid.org/0000-0002-4552-0785)
Hanjue Dai
Qingying Xian (ORCID: https://orcid.org/0000-0001-9836-6163)
Yunqian Chu
Xing Zhang (ORCID: https://orcid.org/0000-0003-4315-6980)
Dongsheng Chen (ORCID: https://orcid.org/0000-0002-2732-1328)
Xuan He (ORCID: https://orcid.org/0000-0002-5895-5139)
Chan Zhu (ORCID: https://orcid.org/0000-0003-4131-3495)
Ya Xue

Institutions

Sichuan University (CN)
West China Hospital of Sichuan University (CN)
Simcere Pharmaceutical (China) (CN)
Changzhou No.2 People's Hospital (CN)
Nanjing Medical University (CN)

Publication Details

Journal: Frontiers in Immunology
Published: 2024-08-26
DOI: https://doi.org/10.3389/fimmu.2024.1448485
Citations: 7
Primary Topic: Gastric Cancer Management and Outcomes
Type: article
Field-Weighted Citation Impact: 2.93

Funders

Jiangsu Commission of Health

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

An exploratory clinical study of β-glucan combined with camrelizumab and SOX chemotherapy as first-line treatment for advanced gastric adenocarcinoma

Chunjian Qi, Wenyu Zhu, Hua Jiang, Hanjue Dai et al.

Aug 26, 2024

7 citations

Frontiers in Immunology

Gastric Cancer Management and Outcomes

2.93

article

An exploratory clinical study of β-glucan combined with camrelizumab and SOX chemotherapy as first-line treatment for advanced gastric adenocarcinoma

Chunjian Qi, Wenyu Zhu, Hua Jiang, Hanjue Dai, Qingying Xian, Yunqian Chu, Xing Zhang, Dongsheng Chen, Xuan He, Chan Zhu, Ya Xue

August 26, 2024article en

7 citations

Abstract

No abstract available for this paper.

Frontiers in ImmunologyVol. 15

Sichuan University (CN), West China Hospital of Sichuan University (CN), Simcere Pharmaceutical (China) (CN), Changzhou No.2 People's Hospital (CN), Nanjing Medical University (CN)

Jiangsu Commission of Health

Good health and well-being

Openalex Percentile: Top 8%

Gastric Cancer Management and Outcomes

2.93

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

An exploratory clinical study of β-glucan combined with camrelizumab and SOX chemotherapy as first-line treatment for advanced gastric adenocarcinoma — Chunjian Qi, Wenyu Zhu, et al. · Frontiers in Immunology (2024) | TGRS Research Map | TGRS